Calls Now Open
2026 Scholar-Innovator, Harrington Prize and ADDF-Harrington
There are over 7,000 known rare diseases, but fewer than 5% have effective treatments, let alone cures. The limited knowledge and consequent lack of treatments available for rare diseases is a major medical and pediatric emergency. Rare diseases are collectively common.
The University of Oxford and Harrington Discovery Institute have formed a unique partnership combining world-leading strengths in research and therapeutics development, to form the Oxford-Harrington Rare Disease Centre. By leveraging our strengths and capabilities, the Oxford-Harrington Rare Disease Centre will advance knowledge leading to drug development in order to advance cures for rare disease.
The Accelerator is a first-in-kind, transatlantic initiative to identify, fund, and advance breakthrough academic discoveries to deliver new treatments for the 400 million people worldwide who suffer from rare diseases. Its goal is to deliver 40 new potentially life-changing therapies for rare diseases into clinical trials over the next ten years and target multiple approvals from regulators in key markets including the US, UK and Europe.
Innovative discovery research and drug development programs will have access to cutting-edge scientific platforms complemented by extensive global partnerships. The Oxford-Harrington Rare Disease Centre will focus efforts on finding treatments and cures for rare diseases that fit within the following criteria:
Fund for Cures UK, Ltd. is Harrington Discovery Institute's UK charity and is the granting organization for the Centre.
Contact us to learn more about the Oxford-Harrington Rare Disease Centre.
Matt Anderson, MD, PhD
Co-Director, Oxford-Harrington Rare Disease Centre; Investigator, Harrington Discovery Institute
Sir John Bell
President, Ellison Institute of Technology, Oxford; Interim Council Chairperson
Georg Holländer, MD
Head of Department of Paediatrics, University of Oxford
Jonathan S. Stamler, MD
President, Harrington Discovery Institute